A5011994741- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer Mechanisms and Therapy
- Peripheral Neuropathies and Disorders
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Bone health and treatments
- Blood groups and transfusion
- Pain Mechanisms and Treatments
- Hereditary Neurological Disorders
- Advanced biosensing and bioanalysis techniques
- PI3K/AKT/mTOR signaling in cancer
- Pharmacological Effects and Toxicity Studies
- Healthcare and Venom Research
- Erythropoietin and Anemia Treatment
- Autoimmune Bullous Skin Diseases
Ministry of Health of the Russian Federation
2023-2025
National Medical Research Center for Hematology
2023-2024
Background. One of the most common causes peripheral neuropathy in multiple myeloma patients is bortezomib‑induced (bIpN), which clinically characterized by paresthesia, a burning sensation, numbness, and primarily pain limbs. This syndrome often associated with development anxiety depression. Aim. To study BIPN determine relationship between mental disorders descriptors at completion stage induction therapy after autologous hematopoietic stem cell transplantation (auto‑HSCT). Materials...
Background. Anemia is the main symptom of multiple myeloma (MM) both at time disease onset and during tumor progression. Previously, method anemia treatment was blood transfusion therapy. Currently, transfusions are supplemented by erythropoietin (EPO) administration. Safety effectiveness drug have been proven in trials including involving oncohematological patients. Aim. To present results using epoetin alpha (Eralfon) patients with MM complicated dialysis-dependent cast nephropathy real...
Multiple myeloma (MM) is a disease characterized by spatiotemporal heterogeneity of tumor clones. Different genetic aberrations can be observed simultaneously in cells from different loci, and as the progresses, new subclones may appear. The role liquid biopsy, which based on analysis DNA circulating blood plasma, continues to explored MM. Here, we present an STR profiles mutation status KRAS, NRAS, BRAF genes, evaluated plasma free (ctDNA), CD138+ bone marrow cells, plasmacytomas....
Multiple myeloma (MM) is characterized by heterogeneity of tumor cells. The study cells from blood, bone marrow, plasmacytoma, etc., allows us to identify similarities and differences in lesions various anatomical localizations. aim this was compare the loss heterozygosity (LOH) assessing STR profiles different MM lesions. We examined paired samples plasma circulating DNA (ctDNA) CD138+ marrow patients. For patients with plasmacytomas (66% 38 included), profile also studied when biopsy were...
Introduction. The analysis of free circulating DNA (cfDNA) holds promise for molecular diagnostics, but its fragmentation and low concentration can complicate PCR analysis. Objective. To investigate the effect target length on amplification efficiency Y-chromosome markers from cfDNA. Material methods . Fifty cfDNA samples were obtained 39 patients: patients after liver transplantation (n=19), with acute leukemia allogeneic hematopoietic stem cell (n=10), pregnant women (n=10). In addition,...
Background: To assess the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients with acute renal failure.
 Materials and Methods: A retrospective single-center study included 64 (30 men, 34 women) MM kidney damage at onset disease, aged 19 to 65 years (median 54), who underwent auto-HSCT from 2013 2019. 23 (36%) were dialysis-dependent time diagnosis. The analysis was carried out two groups: "HD-" group (patients independent...
Background. One of the most common symptoms multiple myeloma (MM) is pain. Bone pain observed in 60– 80 % patients at disease onset. Neuropathic syndrome also often found MM. Aim. To characterize MM onset and various therapy stages. Materials methods. From January 2019 to October 2021 a retrospective single-center study included 105 with newly diagnosed symptomatic (49 men, 56 women) aged from 26 83 years (median 58.5). Induction all was performed bortezomib-containing regimens. High-dose...
Background . Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for trials. Aim To evaluate Isaomex triplet multiple myeloma real practice. Materials and methods From 2021 to 2024, retrospective study included 83 double refractory 26 centers aged 38 85 years (median 63), received triplet. Glomerular filtration rate ˂ 60 mL/min was detected at time isatuximabbased...
Background . Multiple myeloma (MM) is a plasma cell tumour, which could be followed by formation of bone plasmacytomas. Bone plasmacytoma cells proliferate, developed in medullar cavity, destroy cortical layer and escape to the surrounding tissues. Biological characteristics tumour substrate hypothetically influence clinical course MM. Aim To compare laboratory parameters newly diagnosed MM depending on presence or absence Materials methods A retrospective study included 40 patients with...
Background. Medical care through telemedicine technologies for plasma cell tumors has been provided at the National Research Center Hematology since 2018. Patients are consulted “doctor–doctor” level in field of “hematology”. Another important aspect application is scientific, practical and educational activities aimed developing remote interaction with medical institutions, ways to improve specialized organizations. Aim. To present implementation main applications on example paraproteinemic...
BACKGROUND AND AIMS Despite the fact that activating mutations in RAS-ERK cascade genes are quite often detected multiple myeloma (MM), literature data on their prognostic value contradictory.1,2 The tumour substrate should not only be analysed bone marrow and plasmacytoma, but also plasma circulating DNA (ctDNA) for heterogeneity of MM to effectively analysed.3,4 aim was study mutational status KRAS, NRAS, BRAF from different loci MM. MATERIALS METHODS single-centre October 2021–January...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Multiple myeloma (MM), complicated by bone plasmacytomas, is characterized some features. The influence of plasmacytomas on the survival MM patients studied worldwide. A well-known factor unfavorable prognosis in solitary plasmacytoma size: a large has one linear dimensions exceeds 5 cm (D.Knobel et al.,2006). Learning impact size course disease with represents considerable interest. Aims: to evaluate frequency...
Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: Despite the fact that activating mutations in RAS-ERK cascade genes quite often detected MM, literature data on their prognostic value are contradictory. To assess heterogeneity of not only tumor substrate bone marrow plasmacytoma, but also plasma circulating DNA (ctDNA) could be effectively analyzed. Aims: study mutational status KRAS, NRAS, BRAF from different loci MM. Methods: The...